Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain.

Click here to read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext

English version of this podcast:

https://www.buzzsprout.com/1564352/episodes/18730659

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain.

Click here to read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00321-7/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00291-1/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia.

Click here to read the full article

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv